PubMed Health treatment related to Dysentery: 63
You lose fluids and electrolytes when you have diarrhea , so it is important to replace them. For acute , non-severe diarrhea you usually just need something like tea with sugar and some salted crackers. Foods that are gentle on the stomach is recommended too, such as rice, bananas or rusk bread. Some people also avoid coffee, fruit juices, sodas, alcohol and fatty foods to keep from irritating their bowel even more. Acute , non-severe diarrhea does not require special treatment in adults and teenagers. But it is a good idea for young children and older people, as well as people with more severe diarrhea, to replace fluids and electrolytes by using oral rehydration salts (electrolyte /glucose solutions) from the pharmacy. These are powders containing salts, minerals and glucose that can be dissolved in water. If these solutions are not available (for instance, while traveling) the following ingredients can be stirred into one liter of bottled or boiled water: Five tablespoons of sugar One and a half level tablespoons of salt One glass of packaged orange juice In addition to drinking fluids and using other treatments , foods or dietary supplements that have probiotic microorganisms (probiotics ) in them can help to make the diarrhea go away faster. Depending on how severe the symptoms are and how long they last, other treatments may be considered too: Drugs like loperamide or racecadotril can help to slow down the activity of the bowel and lower the number of times you need to go to the bathroom. Loperamide is not suitable for children under the age of twelve years, and racecadotril is prescription-only for children. Sometimes certain types of yeast tablets (Perenterol) are also recommended. These tablets are thought to help the body get rid of the germs faster and to support natural gut flora. Charcoal tablets dissolved in water can also be taken to relieve diarrhea symptoms. But there is a lack of good-quality research in this area so no conclusions can be drawn about the benefits and harms of these treatment options. Antibiotics are only an option if the infection is bacterial. They can't fight viruses .
Drugs for Dysentery (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 69)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Loperamide |
Approved |
Phase 4 |
|
53179-11-6 |
3955 |
Synonyms:
Apo-loperamide
Diamide
FORTASEC
Fortasec®|Imodium®|R-18553
Hydrochloride, loperamide
Imodium
Imodium a-D
Imodium a-D caplets
Kaopectate II
Loperacap
Loperamid
Loperamida
|
Loperamide
Lopéramide
Loperamide hydrochloride
Loperamide monohydrochloride
Loperamidum
Maalox anti-diarrheal
Monohydrochloride, loperamide
Nu-loperamide
PMS-Loperamide
R-18553
Rho-loperamide
|
|
2 |
|
Sodium citrate |
Approved, Investigational |
Phase 4 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
3 |
|
Mebendazole |
Approved, Vet_approved |
Phase 4 |
|
31431-39-7 |
4030 |
Synonyms:
(5-Benzoyl-1H-benzimidazol-2-yl)-carbamate methyl ester
(5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester
Abello farmacia brand OF mebendazole
Anti worm
Anti-worm
Ardeypharm brand OF mebendazole
Bantenol
Banworm
Boots brand OF mebendazole
Boots threadworm treatment
Degort's brand OF mebendazole
Diba brand OF mebendazole
Elfar brand OF mebendazole
EMVERM
Esteve brand OF mebendazole
Healthypharm brand OF mebendazole
Janssen brand OF mebendazole
Leidapharm brand OF mebendazole
Lomper
Madicure
MBDZ
Mebendan
Mebendazol
Mebendazole
|
Mébendazole
MEBENDAZOLE POLYMORPH C
Mebendazolum
Mebenvet
Norgine brand OF mebendazole
NSC-184849
OVEX
Pfizer brand OF mebendazole
Pripsen mebendazole
R-17635
Sqworm
SSL Brand OF mebendazole
Streger brand OF mebendazole
Sufil
Surfont
Taxandria brand OF mebendazole
Tedec meiji brand OF mebendazole
Telmin
TELMINTIC
Vermicol
Vermidil
Vermin
Vermox
Wormkuur
|
|
4 |
|
Piperazine |
Approved, Vet_approved |
Phase 4 |
|
110-85-0 |
4837 |
Synonyms:
1,4 Diazacyclohexane
1,4 Piperazine
1,4-Diazacyclohexane
1,4-Piperazine
Diethylenediamine
Diethyleneimine
Fluphenazine dihydrochloride
Hexahydropyrazine
Piperazidine
Piperazin
Piperazina
Piperazine
Piperazine diacetate
Piperazine dihydrochloride
Piperazine hexahydrate
|
Piperazine hydrate
Piperazine hydrobromide
Piperazine hydrochloride
Piperazine monohydrochloride
Piperazine phosphate
Piperazine phosphate (1:1)
Piperazine phosphate anhydrous
Piperazine salt
Piperazine sulfate
Piperazine tartrate
Piperazine tartrate (1:1), (R-(r*,r*))-isomer
Piperazine tartrate, (R-(r*,r*))-isomer
Piperazinium oleate
Pripsen
Vermizine
|
|
5 |
|
Ciprofloxacin |
Approved, Investigational |
Phase 4 |
|
85721-33-1, 93107-08-5 |
2764 |
Synonyms:
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylate
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylate
1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylIC ACID
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylate
1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Anhydrous, ciprofloxacin hydrochloride
Bacquinor
BAY O 9867 FREE BASE
Baycip
BAY-O-9867 FREE BASE
BAYQ3939
BAY-Q-3939
Bernoflox
CETRAXAL
Ciflox
Cifloxin
CILOXAN
Ciprinol
Cipro
Cipro I.V.
Cipro XL
Cipro XR
CIPROBAY
|
Ciprocinol
Ciprodar
Ciprofloxacin
Ciprofloxacin dihydrochloride
Ciprofloxacin HCl
Ciprofloxacin hydrochloride
Ciprofloxacin hydrochloride anhydrous
Ciprofloxacin monohydrochloride
Ciprofloxacin monohydrochloride monohydrate
Ciprofloxacina
Ciprofloxacine
Ciprofloxacino
Ciprofloxacinum
Cipromycin
Ciproquinol
Ciproxan
Ciproxin
CPFX
CPR867
Flociprin
Floxin
Hydrochloride anhydrous, ciprofloxacin
Hydrochloride, ciprofloxacin
Monohydrate, ciprofloxacin monohydrochloride
Monohydrochloride monohydrate, ciprofloxacin
Ocuflox
OTIPRIO
Proquin XR
Septicide
VELMONIT
Velomonit
|
|
6 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
7 |
|
Antidiarrheals |
|
Phase 4 |
|
|
|
8 |
|
Antimitotic Agents |
|
Phase 4 |
|
|
|
9 |
|
Anthelmintics |
|
Phase 4 |
|
|
|
10 |
|
Antiparasitic Agents |
|
Phase 4 |
|
|
|
11 |
|
Tubulin Modulators |
|
Phase 4 |
|
|
|
12 |
|
Citrate |
|
Phase 4 |
|
|
|
13 |
|
Piperazine citrate |
|
Phase 4 |
|
|
|
14 |
|
DMP 777 |
|
Phase 4 |
|
157341-41-8 |
|
15 |
|
Anti-Retroviral Agents |
|
Phase 4 |
|
|
|
16 |
|
Fluoroquinolones |
|
Phase 4 |
|
|
|
17 |
|
Rifamycin |
Approved, Investigational |
Phase 3 |
|
6998-60-3 |
6324616 |
Synonyms:
Aemcolo®
CB-01-11
M-14
Rifamicina
Rifamicine SV
RIFAMYCIN
|
RIFAMYCIN SV
Rifamycine
Rifamycinum
RIFOMYCIN
Rifomycin SV
|
|
18 |
|
Zinc cation |
Approved, Experimental, Investigational |
Phase 3 |
|
7440-66-6, 23713-49-7 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
Mannosidase b, alpha
Neutral alpha mannosidase
|
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc ion(2+)
Zinc(2+)
Zinc(II)
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
zinc|zinc ion
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
19 |
|
Nitazoxanide |
Approved, Investigational, Vet_approved |
Phase 3 |
|
55981-09-4 |
41684 |
Synonyms:
2-(Acetolyloxy)-N-(5-nitro-2-thiazolyl)benzamide
2-Acetyloxy-N-[(5-nitro-2-thiazolyl)]benzamide
ADROVET
Alinia
Colufase
Columbia brand 1 OF nitazoxanide
Columbia brand 2 OF nitazoxanide
Columbia brand 3 OF nitazoxanide
Cryptaz
Daxon
FARNITOX
Heliton
Nitaxozanid
Nitaxozanide
|
Nitazoxanid
Nitazoxanida
Nitazoxanide
Nitazoxanidum
NODIK
NSC-697855
NTZ
OMNIPARAX
PH-5776
Romark brand 1 OF nitazoxanide
Romark brand 2 OF nitazoxanide
Taenitaz
Tizoxanide glucuronide
|
|
20 |
|
Aluminium phosphate |
Approved, Investigational |
Phase 3 |
|
7784-30-7 |
|
Synonyms:
ALUMINIUM PHOSPHATE
ALUMINIUM PHOSPHATE GEL
|
ALUMINUM PHOSPHATE
PHOSPHALJEL
|
|
21 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
22 |
|
Antirheumatic Agents |
|
Phase 3 |
|
|
|
23 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 3 |
|
|
|
24 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
25 |
|
Antibodies |
|
Phase 3 |
|
|
|
26 |
|
Trace Elements |
|
Phase 3 |
|
|
|
27 |
|
Micronutrients |
|
Phase 3 |
|
|
|
28 |
|
Rifamycins |
|
Phase 3 |
|
|
422447 |
Synonyms:
2,15,17,23-Tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,27,29-trioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1,.0,]triaconta-1(28),2,4,9,19,21,23,25-octaen-13-yl acetic acid
|
|
|
29 |
|
Auranofin |
Approved, Investigational |
Phase 2 |
|
34031-32-8 |
6918453 16667669 70788951 |
Synonyms:
(1-Thio-b-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate
(1-Thio-b-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetic acid
(1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate
(1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetic acid
(1-Thio-β-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate
(1-Thio-β-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetic acid
2,3,4,6-Tetra-O-acetyl-1-thio-b-D-glucopyranosato-S (triethylphosphine)gold
2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold
2,3,4,6-Tetra-O-acetyl-1-thio-β-D-glucopyranosato-S (triethylphosphine)gold
AURANOFIN
Auranofin recordati brand
Auranofin robapharm brand
Auranofin rubio brand
Auranofin yamanouchi brand
Auranofina
Auranofine
Auranofinum
|
Auroafen
Crisinor
Recordati brand OF auranofin
Ridaura
Ridaura®|SK&F-39162|SK-39162
Ridauran
Robapharm brand OF auranofin
Rubio brand OF auranofin
SK And F 39162
SK And F D 39162
SK And F39162
SK And F-39162
SK&F-39162
SK-39162
SmithKline beecham brand OF auranofin
Triethylphosphine gold
Yamanouchi brand OF auranofin
|
|
30 |
|
Histamine |
Approved, Investigational |
Phase 2 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
|
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Eramin
Ergamine
Ergotidine
Histamine
HSM
Imidazole-4-ethylamine
NSC-33792
Β-imidazolyl-4-ethylamine
|
|
31 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 2 |
|
21645-51-2 |
|
Synonyms:
Al(OH)3
Aldrox
Algeldrate
Algeldrate atlas brand
Algeldrate axcan brand
Algeldrate chefaro brand
Algeldrate roques brand
Algeldrate stiefel brand
Algeldrate whitehall brand
Algeldrate wyeth brand
Alhydrogel
ALterna gel
Alugel
Alumina, hydrated
Aluminio hidróxido
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
Aluminiumhydroxid
Aluminum hydroxide
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Amphojel
|
Atlas brand OF algeldrate
Axcan brand OF algeldrate
Basalgel
Brasivil
chefaro Brand OF algeldrate
Dialume
Dried aluminium hydroxide
Dried aluminum hydroxide gel
Dried aluminum hydroxide gel fine granules
Hydrated alumina
Hydroxide, aluminum
Nephrox
Pepsamer
Rhône poulenc rorer brand OF algeldrate
Rhône-poulenc rorer brand OF algeldrate
Rocgel
Roques brand OF algeldrate
Sanofi winthrop brand OF algeldrate
SmithKline beecham brand OF algeldrate
Stiefel brand OF algeldrate
Whitehall brand OF algeldrate
Wyeth brand OF algeldrate
|
|
32 |
|
Azithromycin |
Approved |
Phase 2 |
|
83905-01-5 |
447043 |
Synonyms:
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
Azadose
AZASITE
Azenil
Azifast
Azigram
Azimakrol
Azithramycine
AZITHROMYCIN
AZITHROMYCIN ANHYDROUS
Azithromycin dihydrate
AZITHROMYCIN HYDRATE
Azithromycin monohydrate
Azithromycin pfizer brand
Azithromycine
Azithromycinum
Azitrocin
Azitromicina
Azitromin
AZYTER
Azythromycin
Bayer brand OF azithromycin dihydrate
CLAMELLE
CP 62993
|
CP-62,993
CP-62993
Dihydrate, azithromycin
Funk brand OF azithromycin dihydrate
Goxal
Hemomycin
Lesvi brand OF azithromycin dihydrate
Mack brand OF azithromycin dihydrate
Monohydrate, azithromycin
Pfizer brand OF azithromycin
Pfizer brand OF azithromycin dihydrate
Pharmacia brand OF azithromycin dihydrate
Sumamed
SUNAMED
Toraseptol
Ultreon
Vinzam
Vita brand OF azithromycin dihydrate
XZ 405
XZ 450
XZ-450
Zentavion
Zithromax
Zitromax
Zmax
|
|
33 |
|
Ceftriaxone |
Approved |
Phase 2 |
|
73384-59-5 |
5479530 |
Synonyms:
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulphanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulphanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Anhydrous ceftriaxone sodium
Benaxona
Biotrakson
Boehringer mannheim brand OF ceftriaxone sodium
C18H18N8O7S3
Cefatriaxone
Cefaxona
Ceftrex
Ceftriaxon
Ceftriaxon curamed
Ceftriaxon hexal
Ceftriaxona
Ceftriaxona [INN-Spanish]
Ceftriaxona andreu
Ceftriaxona LDP torlan
CEFTRIAXONE
Ceftriaxone irex
Ceftriaxone sodium
Ceftriaxone sodium, anhydrous
Ceftriaxone, disodium salt
Ceftriaxone, disodium salt, hemiheptahydrate
Ceftriaxonum
|
Ceftriaxonum [INN-Latin]
Ceftriazone
Columbia brand OF ceftriaxone
CTRX
Curamed brand OF ceftriaxone sodium
FIDATO
Fustery brand OF ceftriaxone sodium
Galen brand OF ceftriaxone sodium
Hexal brand OF ceftriaxone sodium
Hoffman la roche brand OF ceftriaxone sodium
Hoffman-la roche brand OF ceftriaxone sodium
Inibsa brand OF ceftriaxone sodium
Irex brand OF ceftriaxone
Lendacin
Longacef
Longaceph
Pisa brand OF ceftriaxone sodium
Rocefalin
Rocefin
Rocephin
Rocephine
Roche brand OF ceftriaxone sodium
Sodium, ceftriaxone
Syntex brand OF ceftriaxone sodium
Tacex
Terbac
|
|
34 |
|
Inulin |
Approved, Investigational, Nutraceutical |
Phase 1, Phase 2 |
|
9005-80-5 |
24763 |
Synonyms:
|
INULIN AND SODIUM CHLORIDE
|
|
35 |
|
Butyric Acid |
Experimental, Investigational |
Phase 2 |
|
107-92-6 |
264 |
Synonyms:
1-Butanoate
1-Butanoic acid
1-Butyrate
1-Butyric acid
1-Propanecarboxylate
1-Propanecarboxylic acid
4:0
Acid, butanoic
Acid, butyric
Acide butanoique
Acide butyrique
Butanate
Butanic acid
Butanoate
Butanoic acid
butanoic acid|butyrate|C4
Butoate
Butoic acid
Buttersaeure
Butyrate
Butyrate, magnesium
Butyrate, sodium
Butyric acid
|
Butyric acid magnesium salt
Butyric acid, sodium salt
Butyricum acidum
C4:0
CH3-[CH2]2-COOH
Dibutyrate, magnesium
Ethylacetate
Ethylacetic acid
FA(4:0)
Honey robber
Kyselina maselna
Magnesium butyrate
Magnesium dibutyrate
N-Butanoate
N-Butanoic acid
N-Butyrate
N-Butyric acid
Propanecarboxylate
Propanecarboxylic acid
Propylformate
Propylformic acid
Sodium butyrate
|
|
36 |
|
Complement System Proteins |
|
Phase 1, Phase 2 |
|
|
|
37 |
|
Complement Factor H |
|
Phase 1, Phase 2 |
|
|
|
38 |
|
Immunosuppressive Agents |
|
Phase 1, Phase 2 |
|
|
|
39 |
|
Neurotransmitter Agents |
|
Phase 2 |
|
|
|
40 |
|
Histamine phosphate |
|
Phase 2 |
|
51-74-1 |
134614 |
Synonyms:
2)
4-(2-AMINOETHYL)IMIDAZOLE BIS(DIHYDROGEN PHOSPHATE)
4-(2-AMINOETHYL)IMIDAZOLE DI-ACID PHOSPHATE
HISTAMINE ACID PHOSPHATE
|
HISTAMINE BIPHOSPHATE
HISTAMINE DIHYDROGEN PHOSPHATE
HISTAMINE DIPHOSPHATE
HISTAMINE PHOSPHATE (1
|
|
41 |
|
Histamine Antagonists |
|
Phase 2 |
|
|
|
42 |
|
Acidophilus |
|
Phase 1, Phase 2 |
|
|
|
43 |
|
Anti-Ulcer Agents |
|
Phase 2 |
|
|
|
44 |
|
Adjuvants, Immunologic |
|
Phase 2 |
|
|
|
45 |
|
Antacids |
|
Phase 2 |
|
|
|
46 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
47 |
|
Cephalosporins |
|
Phase 2 |
|
|
|
48 |
|
beta-Lactams |
|
Phase 2 |
|
|
|
49 |
|
Lactams |
|
Phase 2 |
|
|
|
50 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 92)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Introduction of New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Management of Diarrhoeal Diseases - A Phase IV Surveillance Study |
Completed |
NCT00490932 |
Phase 4 |
Hypo-osmolar ORS |
2 |
Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population |
Completed |
NCT02385058 |
Phase 4 |
Mebendazole;Quinfamide;Placebo |
3 |
Rifaximin in Standard Three-Day Dosing With and Without the Antimotility Drug, Loperamide, in the Treatment of Travelers' Diarrhea |
Completed |
NCT00292344 |
Phase 4 |
Rifaximin and loperamide |
4 |
A Phase 4 Open Label Study to Assess the Safety and Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in People Living With HIV/AIDS (PLWHA) With Non-Infectious Diarrhea |
Completed |
NCT04192487 |
Phase 4 |
Crofelemer delayed-release tablets 125mg |
5 |
An Open Label Randomised Controlled Trial of Azithromycin Versus Ciprofloxacin for the Treatment of Children Hospitalised With Dysentery in Ho Chi Minh City, Vietnam |
Recruiting |
NCT03854929 |
Phase 4 |
Ciprofloxacin;Azithromycin |
6 |
A Parallel, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Probiotic Formula in the Prevention of Traveler's Diarrhea |
Terminated |
NCT01005849 |
Phase 4 |
|
7 |
Single Daily Dose Rifaximin vs. Standard Thrice Daily Dosing for the 3-Day Treatment of Travelers' Diarrhea |
Withdrawn |
NCT00875875 |
Phase 4 |
Rifaximin |
8 |
Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni |
Completed |
NCT02280044 |
Phase 2, Phase 3 |
|
9 |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rifamycin SV MMX for the Treatment of Traveler's Diarrhea |
Completed |
NCT01142089 |
Phase 3 |
Placebo;Rifamycin SV MMX |
10 |
A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System |
Completed |
NCT00993681 |
Phase 3 |
|
11 |
Effect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following recoveryEffect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following Recovery |
Completed |
NCT00321126 |
Phase 3 |
Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks. |
12 |
Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Children |
Completed |
NCT00366730 |
Phase 3 |
Nitazoxanide |
13 |
Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Tablets in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Adults and Adolescents |
Completed |
NCT00366236 |
Phase 3 |
Nitazoxanide |
14 |
Phase 3 Study (Safety, Immunogenicity and Efficacy) of Improved Shigella Conjugate Vaccines in 1-4 Year Olds in Israel |
Completed |
NCT00368316 |
Phase 3 |
|
15 |
A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX® 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Travellers |
Completed |
NCT01208922 |
Phase 3 |
Rifamycin SV-MMX®;Ciprofloxacin |
16 |
A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years |
Recruiting |
NCT05156528 |
Phase 3 |
|
17 |
A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center, Therapeutic Equivalence Study to Compare Rifaximin 200 mg Tablets (Sandoz GmbH) to Xifaxan® 200 mg Tablets (Salix Pharmaceuticals, Inc.) and Placebo in Patients With Travelers' Diarrhea |
Terminated |
NCT02920242 |
Phase 3 |
Rifaximin (Sandoz GmbH) tablet;Rifaximin (Xifaxan);Placebo |
18 |
Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea |
Withdrawn |
NCT02736539 |
Phase 3 |
CBS 2004 (galacto-oligosaccharides);Placebo |
19 |
A Randomized, Blinded, Single-center, Parallel Controlled , Phase Ⅱ Clinical Trial to Evaluate Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged From 3 Months to 5 Years Old |
Completed |
NCT04865497 |
Phase 2 |
|
20 |
Phase IIa Randomized, Single-Blinded, Placebo-Controlled Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa |
Completed |
NCT02736968 |
Phase 2 |
Auranofin |
21 |
Efficacy, Safety and Immunogenicity of GVGH Shigella Sonnei Vaccine (1790GAHB) in a Human Challenge Study of Healthy Non-immune Adults |
Completed |
NCT03527173 |
Phase 2 |
Placebo |
22 |
Safety, Immunogenicity, and Efficacy Studies of WRSS1, a Live Attenuated Shigella Sonnei Vaccine Candidate, in Healthy Thai Adults |
Completed |
NCT01080716 |
Phase 1, Phase 2 |
|
23 |
A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis |
Completed |
NCT02676895 |
Phase 2 |
|
24 |
Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a |
Completed |
NCT02646371 |
Phase 2 |
|
25 |
Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection |
Completed |
NCT00485134 |
Phase 1, Phase 2 |
|
26 |
Therapeutic Induction of Endogenous Antibiotics for Improved Recovery in Shigellosis |
Completed |
NCT00800930 |
Phase 2 |
|
27 |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults |
Completed |
NCT00751777 |
Phase 2 |
|
28 |
Exploratory Study to Evaluate the Effect of L-isoleucine Supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children and in Inducing Innate Immunity |
Completed |
NCT01034228 |
Phase 2 |
|
29 |
Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants |
Completed |
NCT04056117 |
Phase 1, Phase 2 |
|
30 |
Probiotics for Infectious Diarrhea in Children in South India |
Completed |
NCT01130792 |
Phase 1, Phase 2 |
|
31 |
A Phase Two, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System in Travelers to Asia |
Completed |
NCT01040325 |
Phase 2 |
|
32 |
A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of Two Doses 10^5 and 10^7 CFU of SC599 Oral Vaccine, a Live Attenuated Shigella Dysenteriae 1 Vaccine Strain in Healthy Human Adult Volunteers |
Completed |
NCT00210288 |
Phase 2 |
|
33 |
Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea. A Pilot, Dose Finding, Double-blind, Randomized, Multicentre Study |
Completed |
NCT03447821 |
Phase 2 |
400 mg Rifamycin SV dosage;800 mg Rifamycin SV dosage;1200 mg Rifamycin SV dosage |
34 |
Phase 2b Study of the Safety, Immunogenicity, and Efficacy of a Monovalent Synthetic Carbohydrate-based Conjugate Vaccine (SF2a-TT15) for Protection Against Shigella Flexneri 2a Experimental Infection |
Recruiting |
NCT04078022 |
Phase 2 |
|
35 |
A Phase 2a Age Descending Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a in Adults, Children, and Infant Target Population in Endemic Countries. |
Active, not recruiting |
NCT04602975 |
Phase 2 |
|
36 |
A Double-Blind Placebo Controlled Phase 2 Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of a Live-Attenuated Shigella Sonnei Vaccine, WRSs2 and Determine Its Efficacy in a Challenge Model of S. Sonnei 53G in Healthy Adults |
Not yet recruiting |
NCT04242264 |
Phase 2 |
|
37 |
A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis With Shigella Flexneri 2a Strain |
Not yet recruiting |
NCT05182749 |
Phase 1, Phase 2 |
|
38 |
Double Blind, Multi-center Study to Evaluate the Safety and Efficacy of 100 mg Twice Daily Rifamycin SV MMX® Added to Standard ORT Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years |
Not yet recruiting |
NCT04026984 |
Phase 2 |
Rifamycin SV-MMX;Placebo |
39 |
Double Blind Study to Evaluate the Safety and Efficacy of 400 mg Twice Daily Rifamycin SV MMX® Added to Standard Oral Rehydration Therapy (ORT) Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 12 to 17 Years |
Not yet recruiting |
NCT04027894 |
Phase 2 |
Rifamycin SV MMX;Placebo to Rifamycin SV-MMX |
40 |
Tebipenem-pivoxil as an Alternative to Ceftriaxone for Clinically Non-responding Children With Shigellosis: a Randomized Non-inferiority Trial |
Not yet recruiting |
NCT05121974 |
Phase 2 |
Tebipenem Pivoxil;Azithromycin;Ceftriaxon |
41 |
Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIa Vaccination Study |
Terminated |
NCT00866476 |
Phase 2 |
|
42 |
Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIb Challenge Study |
Terminated |
NCT00866242 |
Phase 2 |
|
43 |
A Phase 2a/2b, Randomized, Double-blinded, Placebo-controlled, Trial to Assess the Safety, Immunogenicity and Efficacy of Inactivated Shigella Flexneri 2a Whole Cell (Sf2aWC) Vaccine Administered With and Without Double Mutant E. Coli Heat Labile Toxin (dmLT) in Healthy Adult Subjects |
Withdrawn |
NCT03038243 |
Phase 2 |
|
44 |
A Single-center, Open, Phase I Clinical Trial to Evaluate Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months |
Completed |
NCT03561181 |
Phase 1 |
|
45 |
A Phase I Dose Escalation Study to Assess the Safety and Immunogenicity of the SF2a-TT15 Conjugate Vaccine Against S. Flexneri 2a in Healthy Adult Volunteers |
Completed |
NCT02797236 |
Phase 1 |
|
46 |
A Phase 1, Open Label, Non-randomized, Single Center Study to Evaluate the Safety and Immunogenicity of 1 Booster Vaccination With (GVGH Shigella Sonnei 1790GAHB) Vaccine Administered Intramuscularly in Healthy Adults Previously Primed With Three Doses of the Same Vaccine in Study H03_01TP Compared to 1 Vaccination With (1790GAHB) Administered Intramuscularly Either to Subjects Who Received Placebo in the H03_01TP Study or naïve Subjects Who Were Not Part of H03_01TP Study |
Completed |
NCT03089879 |
Phase 1 |
|
47 |
A Phase 1 Open-label, Dose Escalating Study of Artificial Shigella Flexneri 2a InvaplexAR Administered Intranasally to Healthy, Adult Volunteers to Evaluate Safety and Immunogenicity |
Completed |
NCT02445963 |
Phase 1 |
|
48 |
An Open Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Auranofin Following Oral Dose Administration for 7 Days to Healthy Subjects |
Completed |
NCT02089048 |
Phase 1 |
Auranofin |
49 |
A Phase 1, Randomized, Observer Blinded, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Intramuscularly in Healthy Adults. |
Completed |
NCT02017899 |
Phase 1 |
|
50 |
A Phase 1, Randomized, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults. |
Completed |
NCT02034500 |
Phase 1 |
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Ciprofloxacin
Scopolamine
|
Scopolamine Hydrobromide
|
Cochrane evidence based reviews: dysentery
|